Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

Abstract Background Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, s...

Full description

Bibliographic Details
Main Authors: Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth, Ingo Schmack
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Ophthalmology
Subjects:
Corneal neovascularization
Corneal endothelial cells
Corneal angiogenesis
Vascular endothelial growth factor
Ranibizumab
Bevacizumab
Online Access:http://link.springer.com/article/10.1186/s12886-018-0978-9

Internet

http://link.springer.com/article/10.1186/s12886-018-0978-9

Similar Items